9. ACQUISITION (Details)		3 Months Ended		9 Months Ended
	Nov. 23, 2015 USD ($) employee patent	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2014 USD ($) $ / shares	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2014 USD ($) $ / shares
Acquisition disclosure
Cash paid for acquisition				$ 7,343,000
Contingent consideration liability		$ 5,800,000		5,800,000
Assets acquired and liabilities assumed
Goodwill		8,030,000		8,030,000
MikaMonu
Acquisition disclosure
Number of former employees receiving retention payments | employee	3
Cash paid for acquisition	$ 5,000,000
Contingent consideration, acquisition date fair value	2,500,000
Amount of payment held in escrow	$ 484,000
Term of additional contingent payments	4 years
Discount rate (as a percent)	14.80%
Contingent consideration liability	$ 5,800,000
Assets acquired and liabilities assumed
Cash and cash equivalents	1,000
Other receivables	54,000
Property and equipment, net	10,000
Intangible assets	3,500,000
Goodwill	8,030,000
Total assets acquired	11,595,000
Accrued expenses	(10,000)
Net deferred tax liability	(821,000)
Total liabilities assumed	(831,000)
Fair value of net assets acquired	$ 10,764,000
Pro forma financial information
Total net revenues		12,921,000	$ 14,227,000	40,523,000	$ 40,670,000
Net loss		$ (563,000)	$ (166,000)	$ (2,540,000)	$ (3,229,000)
Net loss per share, basic and diluted | $ / shares		$ (0.02)	$ (0.01)	$ (0.11)	$ (0.13)
MikaMonu | Patents
Acquisition disclosure
Discount rate (as a percent)	14.00%
Assets acquired and liabilities assumed
Intangible assets	$ 3,500,000
Useful life	15 years
MikaMonu | Selling, general and administrative
Acquisition disclosure
Acquisition related costs		$ 376,000		$ 394,000
MikaMonu | Other assets.
Acquisition disclosure
Amount of payment held in escrow	$ 2,500,000
MikaMonu | United States
Acquisition disclosure
Number of patents held | patent	12
MikaMonu | Continued employment of Dr. Avidan Akerib
Acquisition disclosure
Contingent consideration	$ 1,200,000
MikaMonu | Product development milestones and revenue targets
Acquisition disclosure
Contingent consideration		1,300,000		1,300,000
Term of additional contingent payments	10 years
MikaMonu | Product development milestones and revenue targets | Maximum
Acquisition disclosure
Contingent consideration		$ 38,800,000		$ 38,800,000
MikaMonu | Product development milestones to be achieved by December 31, 2017
Acquisition disclosure
Contingent consideration	$ 750,000
MikaMonu | Revenue milestones to be achieved by January, 1 2021
Acquisition disclosure
Contingent consideration	2,750,000
MikaMonu | Revenue milestones to be achieved by January, 1 2022
Acquisition disclosure
Contingent consideration	4,000,000
MikaMonu | Quarterly payments based on net revenue | Maximum
Acquisition disclosure
Contingent consideration	$ 30,000,000
Contingent consideration, percent of net revenue	5.00%